Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PD-1 instructs a tumor suppressive metabolic program to restrain AP-1 activity in T cell lymphoma

ABSTRACT: PD-1 instructs a tumor suppressive metabolic program to restrain AP-1 activity in T cell lymphoma

PROVIDER: PRJNA976803 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

PD-1 instructs a tumor suppressive metabolic program to restrain AP-1 activity in T cell lymphoma

Project description:PD-1 instructs a tumor suppressive metabolic program to restrain AP-1 activity in T cell lymphoma

| PRJNA976802 | ENA

PD-1 instructs a tumor suppressive metabolic program to restrain AP-1 activity in T cell lymphoma

Project description:PD-1 instructs a tumor suppressive metabolic program to restrain AP-1 activity in T cell lymphoma

| PRJNA877609 | ENA

PD-1 instructs a tumor suppressive metabolic program to restrain AP-1 activity in T cell lymphoma [ATAC-seq]

Project description:PD-1 instructs a tumor suppressive metabolic program to restrain AP-1 activity in T cell lymphoma [ATAC-seq]

| PRJNA879454 | ENA

PD-1 instructs a tumor suppressive metabolic program to restrain AP-1 activity in T cell lymphoma

Project description:To dissect T cell lymphoma pathogenesis, we previously engineered a genetically controllable murine model of human T-NHL based on tamoxifen-inducible irreversible expression of the T-NHL oncogene ITK-SYK, which enforces strong oncogenic TCR signaling. Three days after ITK-SYK expression, we purified the oncogene-expressing cells by fluorescence-activated cell sorting (FACS) for RNA sequencing.

2023-08-08 | GSE212832 | GEO

PD-1 instructs a tumor suppressive metabolic program to restrain AP-1 activity in T cell lymphoma [ATAC-seq]

2023-08-08 | GSE213180 | GEO

3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Project description:This phase I trial is studying the best dose of 3-AP and the side effects of giving 3-AP together with gemcitabine in treating patients with advanced solid tumors or lymphoma. Drugs used in chemotherapy, such as 3-AP and gemcitabine (GEM), work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. 3-AP may help gemcitabine kill more cancer cells by making the cells more sensitive to the drug. 3-AP may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

| 2026481 | ecrin-mdr-crc

Immunoediting instructs tumor metabolic reprogramming to support immune evasion [smartseq]

Project description:Immunoediting sculpts immunogenicity and thwarts host anti-tumor responses in tumor cells during tumorigenesis; however, it remains unknown whether metabolic programming of tumor cells can be guided by immunosurveillance. Here, we report that T cell-mediated immunosurveillance in early staged tumorigenesis instructs c-Myc upregulation and metabolic reprogramming in tumor cells. This previously unexplored tumor-immune interaction is controlled by a non-canonical IFNg-STAT3 signaling and supports tumor immune evasion. Our findings uncover that immunoediting instructs deregulated bioenergetic programs in tumor cells for empowering them to disarm the T cell-mediated immunosurveillance by imposing metabolic tug-of-war between tumor and infiltrating T cells and forming the suppressive tumor microenvironment.

2022-11-15 | GSE217862 | GEO

Immunoediting instructs tumor metabolic reprogramming to support immune evasion [ExomeSeq]

2022-11-15 | GSE217479 | GEO

Immunoediting instructs tumor metabolic reprogramming to support immune evasion [ATAC-seq]

2022-11-15 | GSE217475 | GEO